With reference to your email regarding the captioned corporate announcement submitted by the Company on 03rd November, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 relating to Appointment of Chief Executive Officer, the Company is filing the revised disclosure incorporating the commencement and conclusion time of the Board Meeting.

05th November, 2026 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 Dear Sir/Madam, Sub: Resubmission of Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Ref: Email regarding Additional Details Required for Corporate Announcement dated 03rd November, 2026 titled "Announcement under Regulation 30 (LODR) - Change in Management". With reference to your email regarding the captioned corporate announcement submitted by the Company on 03rd November, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 relating to Appointment of Chief Executive Officer, the Company is filing the revised disclosure incorporating the commencement and conclusion time of the Board Meeting. We wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of M/s. Alkem Laboratories Limited (the “Company”), at its meeting held on 03rd November, 2026 has appointed Dr. Amrut Naik as the Chief Executive Officer (CEO) and Key Managerial Personnel of the Company with effect from 11th November, 2026. The meeting of the Board of Directors of the Company commenced at 12.20 p.m. and concluded at 01:25 p.m. Further, the details as required in terms of Regulation 30 read with Schedule III, Part A of the SEBI LODR Regulations and SEBI Master Circular bearing HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026 are provided in Annexure I to this letter. The above information is also available on the website of the Company www.alkemlabs.com. Kindly take the same on your records. Sincerely, For Alkem Laboratories Limited Manish Narang President - Legal, Company Secretary & Compliance Officer Encl: a/a Annexure I Sr. No. Particulars Details 1. Name Dr. Amrut Naik 2. Reason for change viz. Appointment appointment, re- appointment, resignation, removal, death or otherwise 3. Date of appointment/ D a t e o f appointment: 11th November, 2026 re-appointment/ cessation (as applicable) and term of Term of Appointment: Duration of the contract appointment/ shall be so long as he is in employment of the reappointment Company. 4. Brief Profile Dr. Amrut Naik is a seasoned global pharmaceutical business leader with 26+ years of hands-on experience in building, scaling, and transforming Global businesses across Branded Formulations, Generics, APIs, Biologics, Vaccines, Specialty, and Innovation-led portfolios. He holds a Ph.D. (Tech) in Pharmacology, Master’s in Pharmaceutical Science and Bachelor’s in Pharmaceutical Science. 5. Disclosure of relationships NA between directors